We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
History of cardiovascular events and cardiovascular risk factors among patients initiating strontium ranelate for treatment of osteoporosis.
- Authors
Jingbo Yu; Jackson Tang; Zhiyi Li; Sajjan, Shiva; O'Regan, Christopher; Modi, Ankita; Sazonov, Vasilisa
- Abstract
Purpose: To estimate the proportion of osteoporosis patients in whom initiating strontium ranelate treatment, under new EMA guidelines, should be contraindicated because of a history of cardiovascular events or risk for cardiovascular events. Materials and methods: This was a retrospective analysis of medical and pharmacy claims using the Clinical Practice Research Datalink database. Patients were included if they had ⩾1 prescription of strontium from September 1, 2008 to August 31, 2013, were aged ⩾50 as of the index date (the date of the first ever strontium ranelate prescription), and had ⩾1 year of medical records pre-index. Cardiovascular events occurring any time pre-index were identified, which included ischemic heart disease, cerebrovascular disease, uncontrolled hypertension, and peripheral arterial disease. Cardiovascular risk factors assessed included 1) diabetes or hypertension any time pre-index; 2) hyperlipidemia in the 12 months pre-index; or 3) obesity in the 12 months pre-index. Results: A total of 7,474 patients were included: 90.4% were women, with an average age of 76.5 years, and 84.5% used osteoporosis therapy, either bisphosphonates or non-bisphosphonates, prior to strontium initiation. A total of 23.6% of patients experienced ⩾1 cardiovascular event prior to strontium initiation; the rate was lower among female patients than in male patients (22.4% vs 35.3%, P<0.01). A total of 45.9% had risk factors for cardiovascular events (without cardiovascular event history). Conclusion: More than one-fifth of osteoporosis patients in the UK who used strontium had a cardiovascular event history, and one-half had cardiovascular risk factors prior to strontium initiation.
- Subjects
CARDIOVASCULAR system; AEROBIC capacity; STRONTIUM ranelate; ORGANOSTRONTIUM compounds; OSTEOPOROSIS
- Publication
International Journal of Women's Health, 2015, Vol 7, p913
- ISSN
1179-1411
- Publication type
Article
- DOI
10.2147/IJWH.S88627